Psychopharmacologic Drugs Advisory Committee

December 13, 2006

Slides

FDA Introductory Remarks, Thomas Laughren M.D. Director, Division of Psychiatry Products, FDA ( PPT ) ( HTM )

Antidepressants and Suicidality in Adults: Data Overview, Lisa Jones, M.D., M.P.H; Medical Reviewer, Division of Psychiatry Products, CDER, FDA ( PPT ) ( HTM )

Antidepressants and Suicidality in Adults: Statistical Safety Reviewer Evaluation, Mark Levenson, Ph.D.; Statistical Safety Reviewer, Division of Biometrics 6 ( PPT ) ( HTM )

Antidepressants and Suicidality in Adults: Medical Reviewer Evaluation, Marc Stone, M.D.; Senior Medical Reviewer, Division of Psychiatry Products ( PPT ) ( HTM )

Summary and Issues for Committee, Thomas P. Laughren, M.D. ( PPT ) ( HTM )

Open Public Hearing

Ellen Hanson ( PPT ) ( HTM )

Deborah J. Gruder ( PPT ) ( HTM )

Daniel J. Reidenberg – National Council for Suicide Prevention ( PPT ) (HTM )

Michele Moore ( PPT ) ( HTM )

Tony Noll ( PPT ) ( HTM )

Sara Bostock ( PPT ) ( HTM )

Kim Witczak ( PPT ) ( HTM )

David Healy – Professor of Psychiatry, Cardiff University ( PPT ) ( HTM )

Lee Spiller – Citizens Commission on Human Rights of Texas ( PPT ) ( HTM )

Jayne Richner ( PPT ) ( HTM )

Vera Sharav - Alliance for Human Research Protection ( PPT ) ( HTM )

Charles F. Reynolds III – American Association for Geriatric Psychiatry ( PPT ) ( HTM )

Robert Gibbons – Univ. of Illinois at Chicago , Center for Health Statistics ( PPT ) ( HTM )

Robert Valuck - University of Colorado ( PPT ) ( HTM )

Charge to Committee ( PPT ) ( HTM )

---

Up | AC Home Page